AMAX 126
Alternative Names: AMAX-126Latest Information Update: 11 Mar 2022
At a glance
- Originator Aveta Biomics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Glioblastoma
Most Recent Events
- 09 Mar 2022 AMAX 126 is available for licensing as of 09 Mar 2022. https://avetabiomics.com/join-us/
- 09 Mar 2022 Aveta Biomics have worldwide rights for their products (Aveta Biomics pipeline)
- 09 Mar 2022 Phase-I/II clinical trials in Glioblastoma in USA (PO) Prior to March 2022 (Aveta Biomics pipeline, March 2022)